The knowledge and practice of medicine has changed immensely over the last 60 years. We can now treat illnesses that were only subject to alleviation. Nowhere has this been greater than in psychiatry. While many areas have made significant contributions, the area of psychopharmacology has been in the forefront since the introduction of chlorpromazine for schizophrenia.
While the progress has been impressive, the downside is the decrease in medical-psychiatric use of forms of psychotherapy, which have become the territory more of other mental health professionals, some of whom have been campaigning for prescription rights. Some would go so far as to claim that psychiatry has become a less caring profession and that this may partly account for recent reduction in the number of medical students enrolling in psychiatry, a trend that seems to have been reversed this year.
The research to develop these drugs is long, complicated, and often without result. But where there is evidence that the drug works better than placebo, attention and funding flow into development and promotion. Particularly where there are competing compounds in the same group, the struggle for attention and prescribing choice is intense. More recently, the funding of many of these studies has come from companies who are brokering them. This is in no way to imply that there is anything wrong with this activity as it is quite in keeping with the mandate of these companies.
Journals everywhere are committed to keeping their readers acquainted with the latest developments and how to make choices for the individual patient and to provide a framework within which to consider the information and promotion by the representatives of the firms. There have been strenuous efforts to combat direct interference in the conduct, preparation, and dissemination of results. There is even more bias if the firms can stop research before it is completed or even censor the results published. There have been a number of prominent cases of just such occurrence.
However, reality is that there are many ways of influencing the prescribers, such as the teaching events at annual meetings, advertising in the journals, and frequent mailings. Organizations have been happy to accept these influences provided there has been preliminary review of the intended general material and clear declaration of sponsorship.
Journals are now accepting this reality, and the distinguished New England Journal of Medicine has announced that it will no longer insist that authors of review articles be unattached to any of the manufacturers. The argument is that those best able to articulate a review today seem to be involved in funded research of this nature. What is now being emphasized is the clear declaration of any funding received for the research submitted in a paper and any affiliation with the activities of these firms. The purpose is to provide readers with enough information to assess the quality of the research for themselves. Accordingly, each Journal paper will state any affiliations of the authors-academic, financial, or employment-and specific information as to any and all sources of funding for the work and research being reported. Broadly, the Journal will make the presentations as transparent as possible.
Another issue that has come up recently is the inclusion of already published work as an insert in the Journal package. These inserts, for which the CPA is paid, will now have a facing sheet indicating that the item is a paid insert and that its distribution with the Journal in no way implies the endorsement of the content either by the Journal or the CPA. The Journal will not allow the pharmaceutical firms to influence what is published in the Journal or, on the contrary, to impede publication of articles, review papers, inserts, or the choice of guest editors for a specific topic in the In Review series.
